Jonathan H Dinsmore

US Patent:

6432711, Aug 13, 2002

Filed:

Nov 1, 1994

Appl. No.:

08/333076

Inventors:

Jonathan H. Dinsmore - Brookline MA
Judson Ratliff - Stoneham MA

Assignee:

Diacrin, Inc. - Charlestown MA

International Classification:

C12N 508

US Classification:

435368, 435325, 435366, 435384, 435386

Abstract:

An embryonic stem cell which may be induced to differentiate homogeneously into a desired primary cell line. The embryonic stem cell may be engineered with DNA, which encodes a protein or polypeptide which promotes differentiation of the stem cell into a specific cell line, such as, for example, a neuronal cell line, a muscle cell line, or a hematopoietic cell line. The DNA may encode a transcription factor found in the particular cell line. In another alternative, a desired cell line is produced from embryonic stem cells by culturing embryonic stem cells under conditions which provide for a three-dimensional network of embryonic stem cells, and then stimulating embryonic stem cells with an agent, such as retinoic acid, or dimethylsulfoxide, which promotes differentiation of the embryonic stem cells into the desired cell line, such as, for example, a neuronal cell line, or a muscle cell line.

US Patent:

6444205, Sep 3, 2002

Filed:

Sep 30, 1998

Appl. No.:

09/163684

Inventors:

Jonathan Dinsmore - Brookline MA
Julie Siegan - Boston MA

Assignee:

Diacrin, Inc. - Charlestown MA

International Classification:

C12N 500

US Classification:

424 937

Abstract:

Methods for using neural cells to treat chronic pain and/or spasticity are described. The neural cells can be derived from any mammal, and are preferably human or porcine in origin. The neural cells preferably are serotonergic cells or are gamma-aminobutryic acid (GABA)âproducing cells. Neural cells can be obtained from adult, juvenile, embryonic or fetal donors. Neural cells can be modified to be suitable for transplantation into a subject. For example, the neural cells can be modified such that an antigen (e. g. , an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a subject is altered (e. g. , by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject or can be genetically modified to produce a factor. In one embodiment, the neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The neural cells of the present invention can be used to treat chronic pain and/or spasticity by delivering the cells into the spinal cord of a subject.

US Patent:

6491912, Dec 10, 2002

Filed:

Mar 16, 1999

Appl. No.:

09/270145

Inventors:

Jonathan Dinsmore - Brookline MA

Assignee:

Diacrin, Inc. - Charlestown MA

International Classification:

A01N 6300

US Classification:

424 937, 435325

Abstract:

Porcine cardiomyocytes and methods for using the cardiomyocytes to treat disorders characterized by insufficient cardiac function are described. The porcine cardiomyocytes are preferably embryonic porcine cardiomyocytes. The porcine cardiomyocytes can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine cardiomyocytes can be modified such that an antigen (e. g. , an MHC class I antigen) on the cardiomyocyte surface which is capable of stimulating an immune response against the cardiomyocytes in a xenogeneic subject is altered (e. g. , by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cardiomyocyte when introduced into the subject. In one embodiment, the porcine cardiomyocytes are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine cardiomyocytes of the present invention can be used to treat disorders characterized by insufficient cardiac function, e. g.

US Patent:

6713245, Mar 30, 2004

Filed:

Jul 6, 1998

Appl. No.:

09/110772

Inventors:

Jan Koopmans - University of Groningen, NL
Douglas B. Jacoby - Wellesley MA
Jonathan Dinsmore - Brookline MA

Assignee:

Diacrin, Inc. - Charlestown MA
University Hospital Groningen

International Classification:

C12N 500

US Classification:

435 11, 435 13, 435374, 436 18, 424 937

Abstract:

The instant methods pertain to an improved methods for storing neural cells, preferably dissociated neural cells, prior to their use in transplantation and to the cells obtained using such methods. One embodiment pertains to methods for storing the neural cells in medium lacking added buffer or added protein, other embodiments feature neural cells which are maintained at 4Â C. prior to cryopreservation and have comparable viability and/or functionality to freshly harvested cells. In addition, methods for storing and/or transplantation of porcine neural cells are described.

US Patent:

6821779, Nov 23, 2004

Filed:

Aug 17, 2001

Appl. No.:

09/743242

Inventors:

Jan Koopmans - Groningen, NL
Douglas B. Jacoby - Wellesley MA
Jonathan Dinsmore - Brookline MA

Assignee:

University Hospital Groningen, Inc. - Groningen
Diacrin, Inc. - Charlestown MA

International Classification:

C12N 500

US Classification:

435374, 424 937, 435 11, 435 12, 435 13, 436 18

Abstract:

The instant methods pertain to improved methods for storing neural cells, preferably dissociated neural cells, prior to their use in transplantation and to the cells obtained using such methods. One embodiment pertains to methods for storing the neural cells in medium lacking added buffer or added protein, other embodiments feature neural cells which are maintained at 4Â C. prior to cryopreservation and have comparable viability and/or functionality to freshly harvest cells. In addition, methods for storing and/or transplantation of porcine neural cells are described.

US Patent:

20020009461, Jan 24, 2002

Filed:

May 2, 2001

Appl. No.:

09/847881

Inventors:

Ole Isacson - Cambridge MA, US
Jonathan Dinsmore - Brookline MA, US

Assignee:

Diacrin, Inc.

International Classification:

A61K039/385
C12N005/06
A61K045/00

US Classification:

424/193100, 424/093700, 435/325000

Abstract:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

US Patent:

20020031497, Mar 14, 2002

Filed:

Apr 26, 2001

Appl. No.:

09/843270

Inventors:

Thomas Fraser - Newton MA, US
Jonathan Dinsmore - Brookline MA, US

Assignee:

Diacrin, Inc.

International Classification:

A61K045/00
C12N005/06

US Classification:

424/093700, 435/325000

Abstract:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

US Patent:

20020136705, Sep 26, 2002

Filed:

Sep 29, 1998

Appl. No.:

09/163272

Inventors:

JONATHAN DINSMORE - BROOKLINE MA, US

International Classification:

A61K035/30
C12N005/06

US Classification:

424/093100, 424/570000, 435/325000

Abstract:

Porcine spinal cord cells and methods for using the cells to treat spinal cord damage due to neurodegeneration resulting from spinal cord injury and neurodegenerative disorders are described. The porcine spinal cord cells are preferably embryonic spinal cord cells obtained from select gestational days. The porcine spinal cord cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine spinal cord cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine spinal cord cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine spinal cord cells of the present invention can be used to treat spinal cord damage due to neurodegeneration in the spinal cord of a xenogeneic subject (e.g., a human having spinal cord injury, amyotrophic lateral sclerosis or multiple sclerosis) by introducing the cells into the spinal cord of the subject.